最新公告:

  没有公告

您现在的位置: 心灵之窗-眼科医生网 >> 眼科常识 >> 第17届全国会 >> 正文
专题栏目
更多内容
相关文章
更多内容
Two Isoforms of Flk-1 Transcripts in Early Diabetic Rat Retinas           ★★★
Two Isoforms of Flk-1 Transcripts in Early Diabetic Rat Retinas
作者:张新媛 文章来源:本站原创 点击数:251 更新时间:2012/9/13
Background We studied expression levels of genes encoding the two isoforms of Flk-1 and the effect on these of an intravitreal injection of triamcinolone acetonide (IVTA), in diabetic rat retinas.
Methods The right eyes of both streptozotocin-induced diabetic and non-diabetic rats received triamcinolone treatment, while the left eyes were sham-treated, thereby providing 4 treatment groups. Three pairs of PCR primers were designed to specifically amplify the total, long and truncated isoforms of rat Flk-1 mRNA. Gene transcriptional levels of the two isoforms were evaluated using quantitative polymerase chain reaction (real time RT-PCR). To detect the gene activities, standard efficiency standard curves were set up for each of the candidate isoforms.
Results  The transcripts level of the long form Flk-1 is about 4.3 times higher than the level of the short form in the sham-treated normal rat retinas The expression of the total, long and short form of Flk-1 was up regulated by 1.5, 1.8 and 0.7 fold respectively in sham-treated diabetic retinas compared with the sham-treated non-diabetic retinas. IVTA inhibited the expression of the total, long and short forms of Flk-1 by 1.2, 2.0 and 0.3 fold respectively in the IVTA-treated diabetic compared to sham-treated retinas. There was no statistically significant difference in the expression of the total and short form of Flk-1 in IVTA treated diabetic/ non diabetic retinas compared with the sham treated diabetic/non diabetic retinas.
Conclusion The long form of Flk-1 is the predominant mediator of VEGF-A in the pathogenesis of DR, and can be significantly inhibited by IVTA treatment. The short form, which cannot be phosphorylated, does not appear to contribute to the pathogenesis of DR. Further research is warranted to establish whether the truncated form of Flk-1 can be used clinically as a dominant negative inhibitor of the effects of Vascular Endothelial Growth Factor.
会议投稿录入:毛进    责任编辑:毛进 
  • 上一篇会议投稿:

  • 下一篇会议投稿:
  • 【字体: 】【发表评论】【加入收藏】【告诉好友】【打印此文】【关闭窗口
      网友评论:(只显示最新10条。评论内容只代表网友观点,与本站立场无关!)

    | 设为首页 | 加入收藏 | 联系站长 | 友情链接 | 版权申明 |
    眼科医生网 眼科医生网版权所有 @ 1998-2012
    部分文章和资源来源于网络,如果侵犯了您的版权,请指出! 站长:毛进
    信息产业部备案
    *京ICP备18030162号